Skip to content

Press

Portfolio-Media Coverage
Ensoma buys a startup to advance ‘in vivo’ cell therapy work
January 6, 2023 Jan 6, 2023 Biopharma Dive
Portfolio-Media Coverage
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
January 5, 2023 Jan 5, 2023 Bloomberg
Portfolio-Press Releases
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
January 5, 2023 Jan 5, 2023
Portfolio-Media Coverage
On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M
January 5, 2023 Jan 5, 2023 Endpoints
Portfolio-Press Releases
SURGE Therapeutics Receives FDA Clearance of IND Application to Initiate Phase 1/2a Study of Intraoperative Immunotherapy in Bladder Cancer
January 4, 2023 Jan 4, 2023
Portfolio-Media Coverage
Can “Gene Writing” Deliver What Gene Editing Can’t?
December 12, 2022 Dec 12, 2022 The Scientist
Portfolio-Media Coverage
Harvard spinout Surge emerges with $26M to make immunotherapy part of cancer surgery
October 21, 2022 Oct 21, 2022 MedCity News
Portfolio-Media Coverage
Surge raises $26M to take anti-cancer extended-release hydrogel into the clinic
October 18, 2022 Oct 18, 2022 Fierce Pharma
Portfolio-Media Coverage
Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery
October 18, 2022 Oct 18, 2022 Endpoints
Portfolio-Media Coverage
Immunotherapy hydrogel developer surges ahead with $26M series A
October 18, 2022 Oct 18, 2022 Bioworld